NEULANDLAB - Neuland Labs.
📢 Recent Corporate Announcements
Neuland Laboratories has scheduled its board meeting and earnings conference call for May 12, 2026, to discuss financial results for the fourth quarter and full fiscal year 2026. The company, a specialized API manufacturer, currently manages over 300 processes and 100 APIs with a significant global footprint in 80 countries. The management call is set for 17:30 IST following the results release. This routine announcement sets the stage for investors to evaluate the company's annual performance and regulatory progress, including its 75 active US DMFs.
- Q4 and Full Year FY26 financial results to be declared on May 12, 2026
- Earnings conference call scheduled for May 12, 2026, at 17:30 hrs IST
- Company maintains a portfolio of 75 active US DMFs and over 995 global regulatory filings
- Neuland operates cGMP facilities with approvals from major global authorities including US FDA and EDQM
Davuluri Ownership Trust, a promoter-related entity of Neuland Laboratories, has submitted its annual compliance certificate for the financial year ended March 31, 2026. This submission follows a SEBI Exemption Order dated January 3, 2025, issued under the Substantial Acquisition of Shares and Takeovers (SAST) Regulations. Independent auditor B Srinivasa Rao & Co. has certified that the Trust met all conditions and disclosure requirements specified by SEBI. This filing ensures the promoter group's compliance with regulatory frameworks regarding shareholding structures.
- Compliance certificate filed for the financial year ended March 31, 2026.
- Relates to SEBI Exemption Order No. WTM/ASB/CFD/17/2024-25 dated January 3, 2025.
- Independent auditor B Srinivasa Rao & Co. confirmed full compliance with SAST Regulations.
- The filing confirms adherence to governance and disclosure requirements for the Davuluri Ownership Trust.
Neuland Laboratories Limited has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, provided by Kfin Technologies Limited, confirms that all dematerialization and rematerialization requests for the quarter ended March 31, 2026, have been processed. This filing is a standard administrative requirement for listed companies in India to ensure the integrity of shareholding records. There are no financial or operational updates contained within this specific announcement.
- Compliance certificate submitted for the quarter ended March 31, 2026.
- Issued by Registrar and Share Transfer Agent (RTA), Kfin Technologies Limited.
- Confirms processing of dematerialization and rematerialization requests as per SEBI norms.
- Filing covers both National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL).
Neuland Laboratories has appointed Saharsh Davuluri as CEO & MD to lead its next growth phase, focusing on New Chemical Entities (NCE) and peptides. The company has successfully tripled its contract services revenue over the last three years and currently manages over 20 commercial contracts. Future growth is backed by a four-phase expansion of peptide capacity and a doubling of process development capabilities. The leadership transition sees former CEO Sucheth Davuluri move to Executive Vice Chairman, ensuring management continuity.
- Contract services revenues tripled during the last 3 years, driven by a shift toward NCE-focused CDMO work.
- Committed to a four-phase expansion of commercial peptide capacity and doubling of process development capabilities.
- Currently operates 3 US FDA-inspected facilities with 1218 KL of total installed capacity.
- The company manages over 20 commercial contracts and has filed over 1000 DMFs globally.
- Strategic goal set to become one of the world’s top five API-focused CDMOs over the next decade.
Neuland Laboratories Limited has announced the closure of its trading window for all designated persons starting April 1, 2026. This action is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the financial results for the quarter and year ending March 31, 2026. The window will remain closed until 48 hours after the financial results are declared to the stock exchanges. The specific date for the Board Meeting to approve these results will be communicated in the future.
- Trading window closure effective from April 1, 2026
- Closure pertains to the financial results for the quarter and year ended March 31, 2026
- Window to reopen 48 hours after the official declaration of financial results
- Complies with SEBI (Prohibition of Insider Trading) Regulations, 2015
Neuland Laboratories has announced its participation in international non-deal roadshows (NDR) organized by B&K Securities. The management will engage with institutional investors in Hong Kong on March 10, 2026, followed by sessions in Singapore on March 11 and 12. These meetings are intended for group and one-on-one discussions regarding the company's business and performance. Such engagements are part of routine investor relations activities to maintain visibility with global financial institutions.
- Non-deal roadshow (NDR) scheduled in Hong Kong on March 10, 2026.
- Two-day investor engagement in Singapore scheduled for March 11 and 12, 2026.
- Meetings facilitated by B&K Securities involving both group and one-on-one formats.
- Disclosure made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements).
Neuland Laboratories has announced the sad demise of Dr. Christopher M Cimarusti, a Non-Executive Non-Independent Director, on February 28, 2026. Dr. Cimarusti had been a member of the company's Board since 2009, providing over 16 years of strategic guidance. He was particularly instrumental in shaping the company's Research and Development (R&D) function during his long tenure. While his loss is significant in terms of institutional memory, the impact on day-to-day operations is expected to be minimal given his non-executive role.
- Dr. Christopher M Cimarusti passed away on February 28, 2026, as per the regulatory filing.
- He served as a Non-Executive Non-Independent Director and was associated with the Board since 2009.
- The company specifically acknowledged his vision and contributions to the R&D function over 16+ years.
- The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Neuland Laboratories reported an 11.4% YoY increase in total income to INR 447.8 crores for Q3FY26, with the CMS (CDMO) segment contributing over 50% of revenue. EBITDA margins compressed to 19% from previous highs, primarily due to a shift in product mix and a one-time INR 10 crore impact from labor codes. Despite a significant 9-month capex of INR 254 crores, the company maintains a strong net cash position of INR 202.6 crores. Management noted that the absence of a specific high-margin CMS product shipment and delays in Paliperidone contributed to the quarterly margin dip.
- Total income grew 11.4% YoY to INR 447.8 crores, driven by commercial CMS projects.
- EBITDA margin stood at 19%; adjusted for a INR 10 crore labor code impact, the margin would be 21%.
- 9-month gross margin remains healthy at 56% compared to 55% in the previous year.
- Significant 9-month capex of INR 254 crores funded largely through internal accruals and customer advances.
- Working capital cycle stretched to 145 days due to higher inventories and uneven delivery flows.
Neuland Laboratories Limited has submitted its monthly report regarding the re-lodgement of transfer requests for physical shares as per SEBI guidelines. For the month ended January 31, 2026, the company's Registrar and Share Transfer Agent, Kfin Technologies, reported zero requests. No requests were received, processed, approved, or rejected during this period. This filing is a procedural compliance requirement and does not impact the company's financial or operational performance.
- Report filed for the month ended January 31, 2026, in compliance with SEBI circular dated July 2, 2025.
- Total number of physical share transfer re-lodgement requests received during the month was NIL.
- Zero requests were processed, approved, or rejected by the Registrar and Share Transfer Agent.
- The filing confirms adherence to the special window provided by SEBI for physical share transfers.
Neuland Laboratories has provided the web link for the audio recording of its earnings conference call held on February 9, 2026. The call addressed the company's financial performance for the third quarter and the nine-month period ending December 31, 2025. This filing is a regulatory requirement under SEBI's disclosure norms to ensure transparency for all shareholders. Investors can access the recording via the company's website to hear management's detailed commentary on business operations.
- Earnings call conducted on February 9, 2026, following the Q3 FY26 result announcement.
- Recording covers the financial period for the quarter and nine months ending December 31, 2025.
- Link made available on the company's official website under the investor meetings section.
- Disclosure submitted in compliance with Regulation 30 of SEBI LODR Regulations, 2015.
Neuland Laboratories reported a challenging Q3FY26 with a significant 60.2% YoY decline in Profit After Tax (PAT) to Rs 40.4 crore. While Total Income grew 11.4% YoY to Rs 447.8 crore, it fell 13.2% on a sequential basis. The company faced severe margin pressure, with EBITDA margins contracting to 19.0% from 30.4% in the previous quarter, driven by an unfavorable product mix and higher operating expenses. Management remains focused on long-term investments despite the current subdued profitability.
- Total Income for Q3FY26 reached Rs 447.8 crore, up 11.4% YoY but down 13.2% QoQ.
- EBITDA fell 5.9% YoY and 45.8% QoQ to Rs 85.0 crore.
- EBITDA margins contracted sharply to 19.0%, down from 22.5% YoY and 30.4% QoQ.
- Profit After Tax (PAT) plummeted 60.2% YoY to Rs 40.4 crore compared to Rs 101.4 crore in Q3FY25.
- Management cited product mix shifts and increased operating expenses as primary reasons for subdued margins.
Neuland Laboratories reported a mixed Q3FY26 with total income rising 11.4% YoY to ₹447.8 crore, supported by growth in the CMS and Prime segments. However, EBITDA margins contracted significantly by 350 bps to 19.0% due to an unfavorable product mix and higher operating expenses. Consequently, PAT for the quarter fell 60% YoY to ₹31.5 crore. Despite the bottom-line pressure, the company remains net debt-free with a cash surplus of ₹202.6 crore and continues to invest in R&D expansion.
- Total Income for Q3FY26 stood at ₹447.8 crore, up 11.4% YoY, while 9MFY26 income reached ₹1,264.4 crore.
- EBITDA margin compressed to 19.0% in Q3FY26 from 22.5% in the previous year's quarter.
- PAT for Q3FY26 dropped 60% YoY to ₹31.5 crore, with 9MFY26 PAT down 35% at ₹150.6 crore.
- CMS segment remains robust with 98 active projects, including 19 commercial molecules and 10 in Phase-3.
- Capital expenditure for 9MFY26 reached ₹254 crore, including plans for a new 140k sq. ft. R&D facility at Genome Valley.
Neuland Laboratories reported a mixed Q3 FY26 with total income growing 11.4% YoY to ₹447.8 crore, but profitability faced significant pressure. EBITDA fell 5.9% YoY to ₹85 crore, with margins contracting sharply to 19.0% from 22.5% a year ago due to an unfavorable product mix and higher operating expenses. Net profit saw a steep decline of 60.2% YoY to ₹40.4 crore, though the previous year's base was higher due to exceptional items. Management remains optimistic about long-term growth driven by the NCE drug substance segment and niche capabilities despite the short-term margin volatility.
- Total Income grew 11.4% YoY to ₹447.8 crore but declined 13.2% on a sequential (QoQ) basis.
- EBITDA margins contracted by 350 bps YoY and 1,140 bps QoQ to 19.0%.
- Profit After Tax (PAT) plummeted 60.2% YoY to ₹40.4 crore from ₹101.4 crore in the previous year.
- Management cited unfavorable product mix and increased operating expenses as primary reasons for margin compression.
- 9MFY26 Total Income reached ₹1,264.5 crore with cumulative EBITDA at ₹284 crore.
Neuland Laboratories reported a consolidated revenue of ₹439.71 crore for Q3 FY26, a 10.5% increase compared to ₹398.03 crore in the same quarter last year. However, Profit After Tax (PAT) saw a sharp decline of 60% YoY to ₹40.57 crore, down from ₹101.59 crore, partly due to a high base effect from an exceptional gain in the previous year. On a sequential basis, revenue fell 14.5% and PAT dropped 58% from Q2 FY26. Rising finance costs and manufacturing expenses further pressured margins during the quarter.
- Consolidated Revenue from Operations grew 10.5% YoY to ₹439.71 crore but declined 14.5% QoQ.
- Net Profit (PAT) plummeted 60% YoY to ₹40.57 crore, impacted by higher operational costs and a lack of exceptional gains seen in the prior year.
- Finance costs spiked to ₹6.79 crore compared to ₹2.22 crore in Q3 FY25, reflecting higher interest or debt obligations.
- 9M FY26 PAT stands at ₹151.33 crore, a 34.8% decrease from ₹232.30 crore in 9M FY25.
- Geographically, USA and North America revenue grew to ₹191.80 crore, while India revenue saw a sharp decline to ₹91.59 crore from ₹172.07 crore in the previous quarter.
Neuland Laboratories Limited has announced its participation in the Nuvama India Conference 2026 scheduled for February 11, 2026. The company's management will engage in both group and one-on-one meetings with institutional investors and analysts in Mumbai. This is a routine regulatory disclosure under SEBI Listing Obligations and Disclosure Requirements. Such interactions are aimed at providing the investment community with updates on the company's business environment and strategic direction.
- Management participation in the Nuvama India Conference 2026 in Mumbai.
- The event is scheduled to take place on February 11, 2026.
- Interaction format includes both Group and One-on-One meetings.
- Disclosure made under Regulation 30 of SEBI (LODR) Regulations, 2015.
Financial Performance
Revenue Growth by Segment
The CMS (CDMO) segment now contributes over 50% of total revenues. Overall operating income for FY25 was INR 1,476.84 Cr, representing a 5.2% decline from INR 1,558.58 Cr in FY24. However, Q2 FY26 achieved 'record high' revenues driven by commercial CMS projects.
Geographic Revenue Split
Exports account for 82% of total revenue. Within exports, the US and Europe are the primary markets, contributing over 89% of total export earnings (approximately 73% of total company revenue).
Profitability Margins
The reported Profit After Tax (PAT) margin for FY25 was 17.61%, with a total PAT of INR 260.11 Cr. This was a decrease from the 19.25% margin (INR 300.08 Cr) recorded in FY24.
EBITDA Margin
The EBITDA margin reached 30% in Q2 FY26, matching the high of 30% seen in FY24. This margin is driven by operating leverage from high-volume commercial CMS projects and a favorable product mix of specialty molecules.
Capital Expenditure
The company invested INR 170.7 Cr in CAPEX during H1 FY26, with INR 91 Cr spent in Q2 FY26 alone. These investments are directed toward strengthening capabilities in complex specialty molecules and peptides.
Credit Rating & Borrowing
CRISIL has assigned a 'Stable' rating. The company has an annual term debt obligation of approximately INR 40 Cr, which is well-covered by expected annual cash accruals exceeding INR 300 Cr.
Operational Drivers
Raw Materials
The company utilizes complex API intermediates and chemical reagents. Specific chemical names and their individual cost percentages are not disclosed in available documents.
Import Sources
Raw materials are sourced from both domestic (India) and global markets. The company actively monitors global market trends to manage volatility in input prices.
Capacity Expansion
Neuland operates 3 US FDA-approved manufacturing facilities in Hyderabad, Telangana. While specific MTPA capacity is not disclosed, the INR 170.7 Cr H1 FY26 CAPEX is focused on expanding capacity for peptides and complex molecules.
Raw Material Costs
Raw material costs are subject to pricing pressure from the global bulk drugs industry. The company employs a multi-sourcing strategy to reduce dependency on single suppliers and mitigate price fluctuations.
Manufacturing Efficiency
The company focuses on process research and development to improve yields. Specific capacity utilization percentages are not disclosed.
Strategic Growth
Growth Strategy
Growth is targeted through the transition of molecules from clinical phases to commercial production within the CMS segment (98 total projects in Q2 FY26). The company is specifically investing in peptide capabilities and complex specialty generic APIs to differentiate from standard generic competitors.
Products & Services
The company sells complex Active Pharmaceutical Ingredients (APIs), intermediates, and provides Contract Development and Manufacturing Organization (CDMO/CMS) services for innovators.
Brand Portfolio
Neuland Laboratories Limited.
New Products/Services
New product focus is centered on the 'peptide space' and complex specialty molecules. The CMS pipeline added 18 commercial molecules as of Q2 FY26.
Market Expansion
Expansion is focused on regulated markets in the US and Europe, supported by market development subsidiaries in the USA (Neuland Laboratories Inc.) and Japan (Neuland Laboratories K.K.).
Strategic Alliances
The company operates through two wholly-owned subsidiaries in the USA and Japan. No third-party joint ventures or associate companies are reported.
External Factors
Industry Trends
The industry is shifting from simple generics to innovation-driven CDMO solutions. Neuland is positioning itself to benefit from this 'significant transformation' by focusing on complex chemistry and commercializing innovator molecules.
Competitive Landscape
The landscape is highly competitive, featuring global API manufacturers and large-scale players from China who exert pricing pressure on bulk drugs.
Competitive Moat
The moat is based on a 40-year track record, 3 US FDA-approved facilities, and deep expertise in complex chemistry (e.g., peptides). This creates high switching costs for innovator clients who require validated GMP manufacturing partners.
Macro Economic Sensitivity
The business is sensitive to global inflation and healthcare spending trends. Rising consumerization of healthcare and government pushes for innovation-driven solutions in India are positive macro drivers.
Consumer Behavior
There is an increasing consumer focus on holistic health and a growing demand for specialty medications, which drives the need for complex APIs.
Geopolitical Risks
Geopolitical events are cited as a potential cause for supply chain disruptions and market volatility in input prices.
Regulatory & Governance
Industry Regulations
Operations are governed by strict US FDA and EMA standards. The company has 988 worldwide filings, including 499 European DMFs and 72 active US DMFs, requiring constant compliance to maintain market access.
Environmental Compliance
The company achieved a global ESG score of 70 out of 100 from S&P Global. It has developed a carbon accounting tool in partnership with CII-IGBC to disclose emissions data.
Legal Contingencies
There are no significant or material orders passed by regulators or courts that impact the company's going concern status or future operations as of the latest report.
Risk Analysis
Key Uncertainties
Key risks include regulatory non-compliance (impacting 82% of revenue), raw material price volatility, and the 'lumpy' or uneven nature of the CMS business which depends on clinical trial success and innovator timelines.
Geographic Concentration Risk
High concentration in the US and Europe, which account for over 73% of total revenue via exports.
Third Party Dependencies
The company is working to reduce dependency on single-source suppliers for raw materials to mitigate supply chain disruptions.
Technology Obsolescence Risk
The company faces risks from rapid technological changes in drug development. It mitigates this through continuous R&D and digital transformation of internal processes.
Credit & Counterparty Risk
Debtor days were 78 in FY25. However, Q2 FY26 saw a deterioration in working capital due to higher receivables (155 days of sales) resulting from uneven order flows.